STARLITE 1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC

BACKGROUND: Complete response (CR) is still a rare event in patients with advanced clear cell renal cell carcinoma (ccRCC). The combination of nivolumab plus cabozantinib was recently approved for the first-line treatment of ccRCC based on the CheckMate 9ER phase 3 study demonstrating improved progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasanov, Elshad, Flynt, Lesley, Slack Tidwell, Rebecca, Hwang, Hyunsoo, Brooks, Roserika, King, Lauren, Solley, Travis, Syed, Mashaal, Yamamura, Yuko, Hayward, Colin, Venkatesan, Aradhana M, Jonasch, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Trials in Progress Abstract Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445563/
http://dx.doi.org/10.1093/oncolo/oyad216.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445563/
http://dx.doi.org/10.1093/oncolo/oyad216.021

Ejemplares similares